No Data
No Data
Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
BOAN BIOTECH: INTERIM REPORT 2024
Shandong Boan Biotechnology Swings to Profit in H1
Boan Biotechnology announced its interim results, with a shareholder's share of profit attributable to RMB 61.672 million, turning losses into profits year on year.
Boan Biotech (06955) released its financial results for the six months ending on June 30, 2024, with a total revenue of 0.363 billion yuan (RMB) in the period, an increase of 38.93% year-on-year. The net profit attributable to the owners of the parent company was 61.672 million yuan, while in the same period last year, the net loss attributable to the owners of the parent company was 0.12 billion yuan. The basic earnings per share were 0.12 yuan.
Boan Biotech Reports Strong Mid-Year Financial Growth
Bo'an Biology (06955.HK) recorded approximately 0.363 billion yuan in interim revenue, a year-on-year growth of 38.9%.
The announcement of Boan Biological (06955.HK) on August 27th shows that as of the six months ended June 30, 2024, the group's revenue was approximately RMB 362.9 million, an increase of approximately RMB 101.7 million compared to the six months ended June 30, 2023, an increase of 38.9%. The increase was mainly due to the continuous growth in sales of Boyouno (BA1101) and Boyoubei (BA6101) in China. The net profit for the six months ended June 30, 2024, was RMB 61.7 million, while the net profit for the six months ended June 30, 2023, was RMB.
No Data
No Data